Abstract:Summary The global burden of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in young children is high. The RSV prevention strategies approved in 2023 will be essential to lowering the global disease burden. In this Series paper, we describe clinical presentation, burden of disease, hospital management, emerging therapies, and targeted prevention focusing on developments and groundbreaking publications for RSV. We conducted a systematic search for literature published in the past 15 years and used a non-systematic approach to analyse the results, prioritising important papers and the most recent reviews per subtopic. Annually, 33 million episodes of RSV LRTI occur in children younger than 5 years, resulting in 3·6 million hospitalisations and 118 200 deaths. RSV LRTI is a clinical diagnosis but a clinical case definition and universal clinical tool to predict severe disease are non-existent. The advent of molecular point-of-care testing allows rapid and accurate confirmation of RSV infection and could reduce antibiotic use. There is no evidence-based treatment of RSV, only supportive care. Despite widespread use, evidence for high-flow nasal cannula (HFNC) therapy is insufficient and increased paediatric intensive care admissions and intubation indicate the need to remove HFNC therapy from standard care. RSV is now a vaccine-preventable disease in young children with a market-approved long-acting monoclonal antibody and a maternal vaccine targeting the RSV prefusion protein. To have a high impact on life-threatening RSV infection, infants at high risk, especially in low-income and middle-income countries, should be prioritised as an interim strategy towards universal immunisation. The implementation of RSV preventive strategies will clarify the full burden of RSV infection. Vaccine probe studies can address existing knowledge gaps including the effect of RSV prevention on transmission dynamics, antibiotic misuse, the respiratory microbiome composition, and long-term sequalae.

Respiratory syncytial virus infection and novel interventions

Revisiting respiratory syncytial virus’s interaction with host immunity, towards novel therapeutics

Outpatient respiratory syncytial virus infections and novel preventive interventions

Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus

Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date

Respiratory syncytial virus entry and how to block it

Active prophylaxis for respiratory syncytial virus: current knowledge and future perspectives

Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development

Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines

Advances in understanding RSV glycoproteins: Insights into viral entry and implications for vaccines and therapeutic development

Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)

Current concepts and progress in RSV vaccine development

Updates on respiratory syncytial virus prophylaxis: the past, present and future

Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies

Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries

The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access

New Approaches to Respiratory Syncytial Virus Prevention and Treatment

An Overview of Respiratory Syncytial Virus Vaccine Development

RSV prevention options for infants and older adults: A specific expanding competitive arena

Respiratory syncytial virus (RSV): a scourge from infancy to old age

Respiratory syncytial virus (RSV) disease and prospects for its control